Bayer Prices Stivarga With Crowded Colon Cancer Market In Mind
This article was originally published in The Pink Sheet Daily
Executive Summary
Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.